[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"sarcomas\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:sarcomas":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,45,83,112,135,164],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":28,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":5},"100621763","phase-1-phase-1ab-study-of-zl-6201-safety-pk-and-preliminary-efficacy-in-sarcoma-and-selected-tumors-100621763",false,"NCT07374848","Phase 1a\u002Fb Study of ZL-6201 Safety, PK, and Preliminary Efficacy in Sarcoma and Selected Tumors","An Open-label, Phase 1a\u002Fb, Multicenter Study of ZL-6201 to Evaluate Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy in Participants With Sarcoma and Selected Solid Tumors","Inclusion Criteria:\n\n* Adult men and women ≥18 years of age at the time of signing the ICF with an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 and a life expectancy \\> 3 months\n* Participants must have histologically confirmed and documented diagnosis of locally advanced unresectable and\u002For metastatic sarcoma or a selected solid tumor\n* Participants must be willing to undergo a tumor biopsy prior to start of treatment or provide archived tumor tissue sample\n* Participants with sarcoma should have received no more than 2 lines of previous systemic therapies in the metastatic setting\n* Participants with selected epithelial solid tumors should have received no more than 3 lines of previous systemic therapy in the metastatic\u002Frelapsed refractory setting\n* Participants must have at least one measurable target lesion as defined by RECIST v1.1\n* Adequate organ and marrow function as listed per protocol\n* Must be negative for HIV, HBV, and HCV\n\nExclusion Criteria:\n\n* Participants with another known malignancy that has required treatment within the last 2 years\n* Symptomatic central nervous system (CNS) metastasis, and\u002For those requiring therapy with corticosteroids or anticonvulsants to control associated symptoms\n* Participants with leptomeningeal metastasis\n* Most recent systemic anti-cancer treatment or investigational products\u002Fdevices less than 3 weeks\n* Prior treatment with a topoisomerase-1 inhibitor antibody drug conjugate\n* Impaired cardiac function or clinically significant cardiac disease within the last 3 months before administration of the first dose of the study treatment\n* Clinically significant pulmonary disease including autoimmune, connective tissue, or inflammatory conditions\n* Pregnant or nursing (lactating) women","ALL","18 Years",{"count":19,"type":20},180,"ESTIMATED","INTERVENTIONAL",[23],"PHASE1","The purpose of this study is to evaluate the safety and tolerability of investigational study drug ZL-6201 for treating sarcoma and solid tumors cancer.",[26,27],"Solid Tumors","Sarcomas",[29,26,30,31,32],"Sarcoma","Phase1","Antibody-Drug Conjugate (ADC)","Leucine-Rich Repeat-Containing protein 15 (LRRC15)","RECRUITING","2026-06-18",{"date":36,"type":37},"2026-06-22","ACTUAL",{"date":39,"type":37},"2026-03-02",{"date":41,"type":20},"2029-09",{"name":43,"class":44},"Zai Lab (Shanghai) Co., Ltd.","INDUSTRY",{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":4,"eligibilityCriteria":51,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":52,"targetDuration":4,"studyType":21,"phases":54,"briefSummary":56,"conditions":57,"keywords":60,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":72,"lastUpdatePostDateStruct":73,"startDateStruct":75,"completionDateStruct":77,"leadSponsor":79,"locationsCount":82},"100635482","effectiveness-of-09-normal-saline-soaking-in-managing-acute-radiation-dermatitis-100635482","NCT07553260","Effectiveness of 0.9% Normal Saline Soaking in Managing Acute Radiation Dermatitis","The Effectiveness of Saline Soaks in Managing Acute Radiation Dermatitis","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Eastern Cooperative Oncology Group (ECOG) performance status 0-1\n* Patients receiving definitive radiotherapy for sarcomas or head and neck cancer (primary or postoperative treatment)\n* Planned radiation dose between 60-70 Gy according to disease-specific protocols\n* No prior history of malignancy other than sarcomas\n* Ability and willingness to comply with study procedures (\\>90% expected adherence)\n* Signed informed consent\n\nExclusion Criteria:\n\n* Patients receiving palliative radiotherapy\n* Known pre-existing skin disorders affecting radiation area (e.g., systemic lupus erythematosus, scleroderma)\n* ECOG performance status ≥2\n* Previous radiotherapy to the same treatment field\n* Any condition that, in the investigator's judgment, may interfere with participation or wound healing assessment",{"count":53,"type":20},150,[55],"NA","The goal of this clinical trial is to learn if normal saline soaks can reduce the severity of acute radiation dermatitis in patients with sarcomas or head and neck cancer receiving radiotherapy. It will also learn if saline soaks can improve wound healing and reduce treatment interruptions caused by skin toxicity. The main questions it aims to answer are:\n\n1. Does the application of normal saline soaks reduce the severity of acute radiation dermatitis according to CTCAE Version 5.0?\n2. Does the use of normal saline soaks improve wound healing time and reduce the frequency and duration of radiotherapy interruptions? Researchers will compare standard care plus saline soaks (intervention group) to standard care alone (control group) to see if saline soaks reduce skin reaction severity and improve clinical outcomes.\n\nParticipants will:\n\n1. Be randomly assigned to receive either standard care alone or standard care with daily saline soaks\n2. Apply saline-soaked gauze to the affected radiation area for 5-10 minutes once daily (intervention group only)\n3. Attend weekly clinic visits for skin assessment during radiotherapy\n4. Be assessed for skin reaction severity, wound healing, and treatment interruptions at baseline, after 4 weeks, and 2 weeks after completing treatment",[58,59,27],"Acute Radiation Dermatitis","Head and Neck Cancer (H&N)",[61,62,63,64,29,65,66,67,68,69,70],"Dermatitis, Radiation-Induced","Skin Diseases, Radiation-Induced","Radiotherapy","Head and Neck Neoplasms","Sodium Chloride","Wound Healing","Skin Care","Moist Desquamation","Supportive Care","Treatment Outcome","NOT_YET_RECRUITING","2026-04-20",{"date":74,"type":37},"2026-04-27",{"date":76,"type":20},"2026-05",{"date":78,"type":20},"2027-06",{"name":80,"class":81},"King Hussein Cancer Center","OTHER",1,{"id":84,"slug":85,"hasResults":11,"nctId":86,"briefTitle":87,"officialTitle":88,"acronym":4,"eligibilityCriteria":89,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":90,"enrollmentInfo":91,"targetDuration":4,"studyType":21,"phases":93,"briefSummary":94,"conditions":95,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":103,"lastUpdatePostDateStruct":104,"startDateStruct":106,"completionDateStruct":108,"leadSponsor":110,"locationsCount":82},"100614228","intrathecal-dexmedetomidine-fentanyl-combination-versus-fentanyl-alone-as-adjuvant-to-bupivacaine-in-spinal-anesthesia-for-above-knee-amputation-in-sarcomas-of-lower-extremity-100614228","NCT07276867","Intrathecal Dexmedetomidine-Fentanyl Combination Versus Fentanyl Alone as Adjuvant to Bupivacaine in Spinal Anesthesia for Above Knee Amputation in Sarcomas of Lower Extremity","Intrathecal Dexmedetomidine-Fentanyl Combination Versus Fentanyl Alone as Adjuvant to Bupivacaine in Spinal Anesthesia for Above Knee Amputation in Sarcomas of Lower Extremity: A Randomized, Comparative Study","Inclusion Criteria:\n\n* Age from 18 to 60 years.\n* Both sexes.\n* American Society of Anesthesiologists (ASA) physical status of II-III.\n* Height between 150-185 cm.\n* Body mass index between 18-35 kg\u002Fm².\n* Scheduled for above-knee amputation due to lower limb sarcomas.\n\nExclusion Criteria:\n\n* Allergy to any of the investigated drugs.\n* History of heart block, arrhythmia, or ongoing therapy with beta- or calcium channel- blockers, or angiotensin-converting-enzyme inhibitors.\n* Contraindications to spinal anesthesia.\n* Pregnancy or lactation.\n* Presence of psychiatric illness or chronic pain conditions.","60 Years",{"count":92,"type":20},58,[55],"The current work evaluated whether the combination of intrathecal dexmedetomidine and fentanyl provides superior postoperative analgesia to fentanyl alone when administered with hyperbaric bupivacaine.",[96,97,98,99,100,101,27,102],"Intrathecal","Dexmedetomidine","Fentanyl","Bupivacaine","Spinal Anesthesia","Above Knee Amputation","Lower Extremity","2025-11-30",{"date":105,"type":37},"2025-12-11",{"date":107,"type":37},"2025-10-20",{"date":109,"type":20},"2026-04-01",{"name":111,"class":81},"National Cancer Institute, Egypt",{"id":113,"slug":114,"hasResults":11,"nctId":115,"briefTitle":116,"officialTitle":117,"acronym":4,"eligibilityCriteria":118,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":119,"targetDuration":4,"studyType":21,"phases":121,"briefSummary":122,"conditions":123,"keywords":4,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":126,"lastUpdatePostDateStruct":127,"startDateStruct":129,"completionDateStruct":131,"leadSponsor":133,"locationsCount":82},"100595051","phase-1-bold-100-plus-doxorubicin-in-advanced-soft-tissue-sarcomas-100595051","NCT07027423","BOLD-100 Plus Doxorubicin in Advanced Soft Tissue Sarcomas","A Phase 1b Trial of BOLD-100 Plus Doxorubicin in Advanced Soft Tissue Sarcomas","Inclusion Criteria\n\n1. Written informed consent in accordance with federal, local, and institutional guidelines.\n2. Age \\> 18 years.\n3. Patients must have histologically confirmed locally advanced\u002Funresectable or metastatic soft tissue sarcoma of limited subtype LMS, DDLPS and UPS (including Myxofibrosarcoma-MFS).\n4. Patients be systemic treatment naïve, with incurable, advanced or metastatic disease.\n5. Patient must have measurable disease as defined by RECIST 1.1.\n6. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.\n7. Adequate hematopoietic function:\n\n   1. total white blood cell (WBC) count ≥2000\u002Fmm3.\n   2. absolute neutrophil count (ANC) ≥1500\u002Fmm3.\n   3. platelet count ≥100,000\u002Fmm3.\n8. Adequate hepatic function:\n\n   1. Bilirubin \\\u003C2 times the upper limit of normal (ULN) (except patients with Gilbert's syndrome who must have a total bilirubin of \\\u003C 3 times ULN).\n   2. Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) \\\u003C2.5 X ULN. In the case of known (radiological and\u002For biopsy documented) liver metastasis, ALT\u002FAST \\\u003C5.0 X ULN is acceptable.\n9. Adequate renal function defined as \\\u003C1.5x upper limits of normal\n10. Cardiac function: A normal left ventricular ejection fraction (LVEF) of \\> 50% as evidenced by an echocardiogram or nuclear medicine study performed within 28 days of the proposed study commencement.\n11. Female patients of childbearing potential must agree to use two methods of contraception (including one highly effective and one effective method of contraception) and have a negative serum pregnancy test at 72 hours prior to receiving the first dose of study medication. Male patients must use an effective barrier method of contraception if sexually active with a female of childbearing potential. For both male and female patients, effective methods of contraception must be used throughout the study and for 3 months following the last dose of study treatment.\n\nExclusion Criteria\n\nSubjects should not enter the study if any of the following exclusion criteria are fulfilled:\n\n1. Patient is pregnant or lactating.\n2. Radiation (except planned or ongoing palliative radiation outside of the region of measurable disease), chemotherapy, immunotherapy, any other systemic anticancer therapy, or participation in an investigational anti-cancer study ≤3 weeks prior to initiation of therapy.\n3. Major surgery within 4 weeks before initiation of therapy.\n4. Prior systemic therapy.\n5. Unstable cardiovascular function:\n\n   1. symptomatic ischemia, or.\n   2. uncontrolled clinically significant conduction abnormalities (e.g., ventricular tachycardia on anti-arrhythmic is excluded and 1st degree AV block or asymptomatic LAFB\u002FRBBB will not be excluded) or.\n   3. congestive heart failure (CHF) of NYHA Class ≥3, or.\n   4. myocardial infarction (MI) within 3 months of initiation of therapy.\n6. Active, ongoing or uncontrolled active infection within one week prior to first dose.\n7. Malignancies other than disease under study within 2 years prior to Cycle 1, Day 1, except for those with a negligible risk of metastasis or death (such as adequately treated carcinoma in situ of the cervix, basal or squamous cell skin cancer, localized prostate cancer, or ductal carcinoma in situ). Prior chemotherapy is allowed apart from regimens that contained anthracycline based therapies.\n8. Known to be HIV seropositive.\n9. Known active hepatitis A, B, or C infection; or known to be positive for hepatitis C virus (HCV) RNA or hepatitis B virus (HBV) surface antigen (HBsAg).\n10. Patients with active CNS malignancy. Asymptomatic small lesions are not considered active. Treated lesions may be considered inactive if they are stable for at least 3 months.\n11. Serious psychiatric or medical conditions that could interfere with treatment.\n12. Concurrent therapy with approved or investigational anticancer therapeutic agents.\n13. Any condition that, in the opinion of the Investigator, would interfere with evaluation of the study regimen or interpretation of patient safety or study results.",{"count":120,"type":20},32,[23],"A Phase 1b, non-randomized, single-institution trial designed to assess the safety, tolerability and the highest dose with acceptable toxicity (RP2D) of BOLD-100 in combination with doxorubicin in patients diagnosed with advanced soft tissue sarcomas. The trial is divided into two phases: an initial dose-escalation phase for BOLD-100, followed by a dose-expansion phase based on the recommended dose for Phase 2. In the dose-escalation phase, we plan to enroll 12-15 patients, with an additional 17 patients in the dose-expansion phase.\n\nParticipants will receive BOLD-100 intravenously on Days 1 and 8 of a 21-day cycle, in combination with doxorubicin (75 mg\u002Fm², intravenous) administered on Day 1 of each 21-day cycle for up to six cycles. Participants will continue to receive BOLD-100 for as long as the cancer is not getting worse, The maximum cycles of doxorubicin are 6 cycles.\n\nParticipants will undergo a screening assessment prior to the start treatment to determine eligibility for enrollment. Treatment will commence on Day 1 and will continue until the protocol-defined criteria for treatment withdrawal are met. Disease response will be assessed using CT or MRI scans, starting at 12 weeks after the initiation of treatment and continuing every 12 weeks until withdrawal.\n\nUpon treatment discontinuation or study withdrawal, a post-treatment assessment will be conducted at end of treatment and at 30 days of the last BOLD-100 dose, with follow-up visits scheduled every 3 months thereafter.",[124,29,125,27],"Sarcoma, Soft-tissue","Sarcoma,Soft Tissue","2025-11-27",{"date":128,"type":37},"2025-12-01",{"date":130,"type":20},"2026-03-30",{"date":132,"type":20},"2027-01-29",{"name":134,"class":81},"University Health Network, Toronto",{"id":136,"slug":137,"hasResults":11,"nctId":138,"briefTitle":139,"officialTitle":140,"acronym":4,"eligibilityCriteria":141,"healthyVolunteers":11,"sex":16,"minAge":142,"maxAge":143,"enrollmentInfo":144,"targetDuration":4,"studyType":21,"phases":146,"briefSummary":147,"conditions":148,"keywords":151,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":154,"lastUpdatePostDateStruct":155,"startDateStruct":157,"completionDateStruct":159,"leadSponsor":161,"locationsCount":163},"100528103","phase-1-cabozantinib-with-ifosfamide-in-relapsedrefractory-sarcomas-100528103","NCT06156410","Cabozantinib With Ifosfamide in Relapsed\u002FRefractory Sarcomas","A Phase I Trial of Cabozantinib (XL184) in Combination With High-dose Ifosfamide in Adults and Children With Relapsed\u002FRefractory Sarcomas (CaIRS Trial)","Inclusion Criteria:\n\n1. Histologic diagnosis of any sarcoma, including bone and soft tissue sarcomas. Biopsy from current relapse\u002Fprogression is highly preferred, though will accept tissue from prior relapse\u002Fprogression or initial diagnosis with approval from the study Principal Investigator or designee.\n2. Disease that has progressed on or relapsed after upfront initial therapy, which must have included traditional chemotherapy.\n3. Evaluable or Measurable disease, according to Response Evaluation Criteria in Solid Tumors (RECIST v1.1), within 21 days of enrollment.\n4. Age, within the following parameters by cohort:\n\n   1. Phase I dose-finding cohort: age 12 to 40 years at the time of enrollment.\n   2. Phase I dose-confirmation cohort: age 5 to \\\u003C 12 years at the time of enrollment.\n5. Body surface area (BSA): \\> 0.35 m2.\n6. Performance status: Lansky play (\\\u003C 16 years of age) or Karnofsky (\\> 16 years of age) of ≥ 50, corresponding to Eastern Cooperative Oncology Group (ECOG) categories \\\u003C 2.\n7. Prior toxicity: recovery to baseline or grade \\\u003C 1, as per the Common Terminology Criteria for Adverse Events (CTCAE) version 5.0 (v5.0), from all acute toxicities, unless adverse events (AE) are clinically non-significant (i.e. alopecia) or controlled on supportive care (i.e. nausea\u002Fvomiting, hypothyroidism).\n8. Able to swallow tablets whole.\n9. Hematopoietic function:\n\n   1. Absolute neutrophil count \\> 1,000\u002FuL (without hematopoietic growth factor within the time frame noted below).\n   2. Hemoglobin \\> 8 g\u002FdL (without transfusion in the last 7 days).\n   3. Platelets \\> 100,000\u002FuL (without transfusion in the last 7 days).\n10. Renal function:\n\n    1. Normal renal function determined by one of the following means (even if others are outside of normal range): 1) serum creatinine \\\u003C 1.5 x upper limit of normal (ULN) for age; 2) cystatin C within normal limits; 3) nuclear medicine glomerular filtration rate (GFR) within normal limits, or 4) calculated creatinine clearance of \\> 70 mL\u002Fmin\u002F1.73 m2 (≥ 1.17mL\u002Fsec)\n    2. Urine protein\u002Fcreatinine ratio (UPCR) ≤ 1 mg\u002Fmg (≤ 113.2 mg\u002Fmmol), or 24-hour urine protein ≤ 1 g.\n11. Hepatic function:\n\n    1. Total bilirubin \\\u003C 1.5 x ULN (for subjects with Gilbert's disease \\\u003C 3.0 x ULN).\n    2. Alanine aminotransferase (ALT), aspartate aminotransferase (AST), and alkaline phosphatase (ALP) ≤ 3 x ULN (ALP ≤ 5 x ULN is allowed with documented bone metastases). For the purpose of this study, the ULN for ALT is defined as 45 IU\u002FL.\n    3. Serum albumin \\> 2.8 g\u002FdL.\n    4. Prothrombin time (PT) and partial thromboplastin time (PTT) \\\u003C 1.3 x ULN.\n12. Sexually active fertile subjects and their partners must agree to use medically accepted methods of contraception (i.e. barrier methods, including male condom, female condom, or diaphragm with spermicidal gel) during the course of the study and for 4 months after the last dose of study treatment.\n13. Female subjects of childbearing potential must not be pregnant at screening. Female subjects are considered to be of childbearing potential unless one of the following criteria are met:\n\n    1. Pre-pubertal by tanner staging, defined as Tanner stage 1 or 2.\n    2. Documented permanent sterilization (i.e. hysterectomy, bilateral salpingectomy, or bilateral oophorectomy). Documentation of permanent sterilization or postmenopausal status may include review of medical records, medical examinations, or medical history interview by study site.\n\nExclusion Criteria:\n\n1. Radiographic evidence of tumor invading major blood vessels, or endotracheal or endobronchial tumor.\n2. Radiographic evidence of tumor invading the gastrointestinal tract, including esophagus, stomach, small or large bowel, rectum, or anus.\n3. Known brain metastases or cranial epidural disease unless adequately treated with radiotherapy or surgery (including radiosurgery) and stable for at least 4 weeks prior to enrollment after radiotherapy or major surgery (i.e. removal or biopsy of brain metastasis). Eligible subjects must be neurologically asymptomatic and without corticosteroid treatment at the time of enrollment.\n4. Prior progression\u002Frelapse with cabozantinib. Prior therapy with cabozantinib without progression\u002Frelapse and prior use of other multi-tyrosine kinase inhibitors is allowed.\n5. Prior therapy with high-dose ifosfamide (\\> 10 g\u002Fm2\u002Fcycle) at any point.\n6. Any small molecule inhibitor therapy within 5 half-lives of the drug or 14 days, whichever is shorter, before enrollment.\n7. Myelosuppressive chemotherapy within 14 days before enrollment.\n8. Autologous bone marrow transplant (auto-BMT) within 42 days before enrollment.\n9. Immunotherapy, including chimeric antigen receptor T-cells (CAR-T), within 21 days before enrollment.\n10. Small port radiation therapy within 14 days before enrollment. Substantial bone marrow radiation (i.e. \\> 50% of the pelvis) or craniospinal radiation within 4 weeks before enrollment. Subjects with any clinically relevant ongoing complications from prior radiation therapy should not be treated with cabozantinib until these complications have resolved.\n11. Major surgery (i.e. abdominal surgery; excluding intracranial surgery as noted above) within 14 days before enrollment. Minor surgeries (including mediport or tunneled catheter placement; excluding needle biopsy for tumor sampling or peripherally inserted central catheter placement) within 10 days before enrollment. Subjects must have documented complete wound healing from major surgery or minor surgery before enrollment.\n12. Hematopoietic growth factors within 7 days (for short-acting growth factor) or 14 days (for long-acting growth factor) before enrollment.\n13. Previously identified allergy or hypersensitivity to components of the study treatment formulations. See Table 10 in Section 9.1.4 for components of cabozantinib.\n14. History of clinically significant hemorrhagic cystitis, defined as grade \\> 3 non-infectious cystitis, associated with antineoplastic agents.\n15. Any medications that are strong CYP3A4 inducers or inhibitors or medications definitely known to cause QTc prolongation.\n16. Concomitant anticoagulation with coumarin agents (i.e. warfarin), direct thrombin inhibitors (i.e. dabigatran), certain direct factor Xa inhibitors (betrixaban), or platelet inhibitors (i.e. clopidogrel). Allowed anticoagulants are the following:\n\n    1. Prophylactic use of low-dose aspirin for cardio-protection (per local applicable guidelines) and low-dose low molecular weight heparins (LMWH).\n    2. Therapeutic doses of LMWH and certain direct factor Xa inhibitors (rivaroxaban, edoxaban, apixaban) in subjects without known brain metastases who are on a stable dose of the anticoagulant for at least 1 week before enrollment without clinically significant hemorrhagic complications from the anticoagulation regimen or the tumor.\n17. Cardiovascular disease, including:\n\n    1. Class III or IV congestive heart failure (New York Heart Association grading).\n    2. Congenital prolonged QT syndrome, clinically significant cardiac arrhythmia, or prolonged corrected QT (QTc) within 14 days before enrollment.\n    3. Uncontrolled hypertension, defined as sustained blood pressure \\> 95th percentile for age, height, and gender for pediatric subjects and \\> 140\u002F90 mmHg for adult subjects, despite optimal antihypertensive treatment.\n    4. Stroke, transient ischemic attack (TIA), myocardial infarction (MI), unstable angina pectoris, or other ischemic or thromboembolic event (excluding those associated with a central line) within 6 months before enrollment.\n18. Gastrointestinal disease, including:\n\n    1. Active peptic ulcer disease, inflammatory bowel disease (Crohn's disease, ulcerative colitis), diverticulitis, cholecystitis, symptomatic cholangitis, appendicitis, or acute pancreatitis.\n    2. Acute obstruction of the pancreatic duct or common bile duct, or gastric outlet obstruction.\n    3. Intra-abdominal abscess within 6 months before enrollment. Complete healing of an intra-abdominal abscess must be confirmed before enrollment.\n    4. Any other condition associated with a high risk of perforation, fistula formation, or potential for decreased absorption of cabozantinib, such as tumors invading the GI tract and ongoing visceral complications from prior radiation therapy.\n19. Bleeding conditions, including:\n\n    1. Clinically significant hematuria, hematemesis, or hemoptysis of \\> 0.5 teaspoon (2.5 ml) of red blood, or other history of significant bleeding (i.e. pulmonary hemorrhage) within 12 weeks before enrollment.\n    2. Radiographic evidence of acute intracranial hemorrhage. In the absence of clinical symptoms, a baseline CT\u002FMRI brain need not be obtained.\n20. Any other active malignancy at time of enrollment or diagnosis of another malignancy within 3 years prior to enrollment that requires active treatment, except for locally curable cancers that have been apparently cured, such as basal or squamous cell skin cancer, superficial bladder cancer, or carcinoma in situ of the prostate, cervix, or breast.\n21. Other clinically significant disorders that would preclude safe study participation, including:\n\n    1. Cavitating pulmonary lesion.\n    2. Serious non-healing wound\u002Fulcer\u002Fbone fracture.\n    3. Uncompensated\u002Fsymptomatic hypothyroidism.\n    4. Moderate to severe hepatic impairment (Child-Pugh B or C).\n    5. Recipient of solid organ transplant, known human immunodeficiency virus (HIV) seropositivity, and other non-treatment related immunodeficiencies.\n    6. Severe or uncontrolled infection or systemic disease.\n    7. Inadequate electrolyte balance, defined as abnormal levels of serum potassium, calcium, magnesium, and phosphorous and causing clinically significant symptoms, acid-base disturbances, or changes in ECG.\n22. Women who are currently pregnant or breastfeeding.","5 Years","40 Years",{"count":145,"type":20},30,[23],"The purpose of this study is to better understand how safe and effective the drug cabozantinib in combination with high-dose ifosfamide is in the treatment of children and adults with relapsed\u002Frefractory sarcomas.",[149,150,27],"Ewing Sarcoma","Osteosarcoma",[152,153],"relapsed","refractory","2025-11-12",{"date":156,"type":37},"2025-11-14",{"date":158,"type":37},"2023-10-24",{"date":160,"type":20},"2028-11",{"name":162,"class":81},"Children's Hospital of Philadelphia",4,{"id":165,"slug":166,"hasResults":11,"nctId":167,"briefTitle":168,"officialTitle":169,"acronym":4,"eligibilityCriteria":170,"healthyVolunteers":11,"sex":171,"minAge":17,"maxAge":172,"enrollmentInfo":173,"targetDuration":4,"studyType":21,"phases":175,"briefSummary":176,"conditions":177,"keywords":179,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":184,"lastUpdatePostDateStruct":185,"startDateStruct":187,"completionDateStruct":189,"leadSponsor":191,"locationsCount":82},"100579850","cryopreserved-ovarian-tissue-transplantation-in-patients-who-have-survived-sarcomas-and-hematological-tumors-100579850","NCT06829654","Cryopreserved Ovarian Tissue Transplantation in Patients Who Have Survived Sarcomas and Hematological Tumors","Safety Assessment Of Cryopreserved Ovarian Tissue Transplantation In Patients Who Have Survived Sarcomas And Hematological Tumors","Inclusion Criteria:\n\nFor all groups:\n\n* Patients with Ewing (ES) and synovial (SS) sarcoma, acute lymphoblastic leukemia (LLA), acute myeloid leukemia (LMA), chronic myeloid leukemia (LMC) and myelodysplasia (MDS)\n* No objection to the procedure of sampling for cryopreservation or reimplantation of ovarian tissue by the patient's reference oncologist (according to PA105)\n* Obtaining informed consent.\n\nGroup 1:\n\n* Age \\>18 and under 38 at the time of cryopreservation\n* Request for cryopreservation of ovarian tissue at the Laboratory Cryopreservation Ovarian Tissue and Cell Cultures\u002FCriobank IRCCS AOUBO\n\nGroup 2:\n\n* Age \\>18 years\n* Ovarian tissue already collected and cryopreserved at the Laboratory for Cryopreservation of Ovarian Tissue and Cell Cultures\u002FCriobank IRCCS AOUBO\n\nGroup 3\n\n* Age \\> 18 years\n* Request for reimplantation of cryopreserved ovarian tissue at the Laboratory for Cryopreservation of Ovarian Tissue and Cell Cultures\u002FCriobank IRCCS AOUBO\n* Early menopause or menstrual irregularities\n\nExclusion Criteria:\n\nGroup 1 and 3\n\n* Contraindications to laparoscopy\n* HIV, hepatitis B and C, treponema pallidum and positive PAP tests\n* Malignant disease involving the ovary or samples to be reimplanted\n\nGroup 2 None.","FEMALE","38 Years",{"count":174,"type":20},80,[55],"The study aims to test for the presence or absence of primary tumor-specific tumor markers in ovarian tissue. Therefore, there will be a first phase in which pathology-specific markers will be identified in the patients' diagnostic pathological material by histological, immunohistochemical, and molecular analysis; then, tumor markers will be sought in cryopreserved ovarian tissue.",[27,178],"Haematological Malignancies",[180,181,182,183],"sarcomas","haematological malignancies","cryopreservation","ovarian tissue","2025-02-11",{"date":186,"type":37},"2025-02-17",{"date":188,"type":37},"2024-08-12",{"date":190,"type":20},"2026-08-12",{"name":192,"class":81},"IRCCS Azienda Ospedaliero-Universitaria di Bologna"]